157 related articles for article (PubMed ID: 36093650)
1. Unfavorable prognosis and clinical consequences of APOBEC3B expression in breast and other cancers: A systematic review and meta-analysis.
Jafarpour S; Yazdi M; Nedaeinia R; Ghobakhloo S; Salehi R
Tumour Biol; 2022; 44(1):153-169. PubMed ID: 36093650
[TBL] [Abstract][Full Text] [Related]
2. Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
Kim SH; Ahn S; Suh KJ; Kim YJ; Park SY; Kang E; Kim EK; Kim IA; Chae S; Choi M; Kim JH
Breast Cancer Res Treat; 2020 Oct; 183(3):697-704. PubMed ID: 32715441
[TBL] [Abstract][Full Text] [Related]
3. The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.
Liu J; Sieuwerts AM; Look MP; van der Vlugt-Daane M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
PLoS One; 2016; 11(8):e0161731. PubMed ID: 27552096
[TBL] [Abstract][Full Text] [Related]
4. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers.
Sieuwerts AM; Willis S; Burns MB; Look MP; Meijer-Van Gelder ME; Schlicker A; Heideman MR; Jacobs H; Wessels L; Leyland-Jones B; Gray KP; Foekens JA; Harris RS; Martens JW
Horm Cancer; 2014 Dec; 5(6):405-13. PubMed ID: 25123150
[TBL] [Abstract][Full Text] [Related]
5. APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers.
Tsuboi M; Yamane A; Horiguchi J; Yokobori T; Kawabata-Iwakawa R; Yoshiyama S; Rokudai S; Odawara H; Tokiniwa H; Oyama T; Takeyoshi I; Nishiyama M
Breast Cancer; 2016 Sep; 23(5):780-8. PubMed ID: 26476745
[TBL] [Abstract][Full Text] [Related]
6. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation.
Cescon DW; Haibe-Kains B; Mak TW
Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2841-6. PubMed ID: 25730878
[TBL] [Abstract][Full Text] [Related]
7. Aberrant APOBEC3B Expression in Breast Cancer Is Linked to Proliferation and Cell Cycle Phase.
Roelofs PA; Timmermans MAM; Stefanovska B; den Boestert MA; van den Borne AWM; Balcioglu HE; Trapman AM; Harris RS; Martens JWM; Span PN
Cells; 2023 Apr; 12(8):. PubMed ID: 37190094
[TBL] [Abstract][Full Text] [Related]
8. Expression of APOBEC3B mRNA in Primary Breast Cancer of Japanese Women.
Tokunaga E; Yamashita N; Tanaka K; Inoue Y; Akiyoshi S; Saeki H; Oki E; Kitao H; Maehara Y
PLoS One; 2016; 11(12):e0168090. PubMed ID: 27977754
[TBL] [Abstract][Full Text] [Related]
9. APOBEC3B promotes hepatocarcinogenesis and metastasis through novel deaminase-independent activity.
Ma W; Ho DW; Sze KM; Tsui YM; Chan LK; Lee JM; Ng IO
Mol Carcinog; 2019 May; 58(5):643-653. PubMed ID: 30575099
[TBL] [Abstract][Full Text] [Related]
10. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.
Caswell DR; Gui P; Mayekar MK; Law EK; Pich O; Bailey C; Boumelha J; Kerr DL; Blakely CM; Manabe T; Martinez-Ruiz C; Bakker B; De Dios Palomino Villcas J; I Vokes N; Dietzen M; Angelova M; Gini B; Tamaki W; Allegakoen P; Wu W; Humpton TJ; Hill W; Tomaschko M; Lu WT; Haderk F; Al Bakir M; Nagano A; Gimeno-Valiente F; de Carné Trécesson S; Vendramin R; Barbè V; Mugabo M; Weeden CE; Rowan A; McCoach CE; Almeida B; Green M; Gomez C; Nanjo S; Barbosa D; Moore C; Przewrocka J; Black JRM; Grönroos E; Suarez-Bonnet A; Priestnall SL; Zverev C; Lighterness S; Cormack J; Olivas V; Cech L; Andrews T; Rule B; Jiao Y; Zhang X; Ashford P; Durfee C; Venkatesan S; Temiz NA; Tan L; Larson LK; Argyris PP; Brown WL; Yu EA; Rotow JK; Guha U; Roper N; Yu J; Vogel RI; Thomas NJ; Marra A; Selenica P; Yu H; Bakhoum SF; Chew SK; Reis-Filho JS; Jamal-Hanjani M; Vousden KH; McGranahan N; Van Allen EM; Kanu N; Harris RS; Downward J; Bivona TG; Swanton C
Nat Genet; 2024 Jan; 56(1):60-73. PubMed ID: 38049664
[TBL] [Abstract][Full Text] [Related]
11. The DNA deaminase APOBEC3B interacts with the cell-cycle protein CDK4 and disrupts CDK4-mediated nuclear import of Cyclin D1.
McCann JL; Klein MM; Leland EM; Law EK; Brown WL; Salamango DJ; Harris RS
J Biol Chem; 2019 Aug; 294(32):12099-12111. PubMed ID: 31217276
[TBL] [Abstract][Full Text] [Related]
12. Integrated Analysis Reveals That Long Non-Coding RNA TUBA4B Can Be Used as a Prognostic Biomarker in Various Cancers.
Zhang T; Wu DM; Deng SH; Han R; Liu T; Li J; Xu Y
Cell Physiol Biochem; 2018; 49(2):530-544. PubMed ID: 30157490
[TBL] [Abstract][Full Text] [Related]
13. Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells.
Yamazaki H; Shirakawa K; Matsumoto T; Hirabayashi S; Murakawa Y; Kobayashi M; Sarca AD; Kazuma Y; Matsui H; Maruyama W; Fukuda H; Shirakawa R; Shindo K; Ri M; Iida S; Takaori-Kondo A
Sci Rep; 2019 May; 9(1):7122. PubMed ID: 31073151
[TBL] [Abstract][Full Text] [Related]
14. APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression.
Yamazaki H; Shirakawa K; Matsumoto T; Kazuma Y; Matsui H; Horisawa Y; Stanford E; Sarca AD; Shirakawa R; Shindo K; Takaori-Kondo A
PLoS One; 2020; 15(1):e0223463. PubMed ID: 31914134
[TBL] [Abstract][Full Text] [Related]
15. p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells.
Periyasamy M; Singh AK; Gemma C; Kranjec C; Farzan R; Leach DA; Navaratnam N; Pálinkás HL; Vértessy BG; Fenton TR; Doorbar J; Fuller-Pace F; Meek DW; Coombes RC; Buluwela L; Ali S
Nucleic Acids Res; 2017 Nov; 45(19):11056-11069. PubMed ID: 28977491
[TBL] [Abstract][Full Text] [Related]
16. Change of Circulating and Tissue-Based miR-20a in Human Cancers and Associated Prognostic Implication: A Systematic Review and Meta-Analysis.
Zhang Q; Wang Q; Sun W; Gao F; Liu L; Cheng L; Li Z
Biomed Res Int; 2018; 2018():6124927. PubMed ID: 30596096
[TBL] [Abstract][Full Text] [Related]
17. Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis.
Sun S; Dong H; Yan T; Li J; Liu B; Shao P; Li J; Liang C
BMC Med Genet; 2020 Jun; 21(1):139. PubMed ID: 32600280
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of APOBEC3A and 3B expression in patients with breast cancer.
Kim YS; Sun S; Yoon JS; Ko YH; Won HS; Kim JS
PLoS One; 2020; 15(3):e0230261. PubMed ID: 32176735
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation.
Matsumoto T; Shirakawa K; Yokoyama M; Fukuda H; Sarca AD; Koyabu S; Yamazaki H; Kazuma Y; Matsui H; Maruyama W; Nagata K; Tanabe F; Kobayashi M; Shindo K; Morishita R; Sato H; Takaori-Kondo A
Sci Rep; 2019 Jun; 9(1):8307. PubMed ID: 31165764
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of AGR2 expression in solid tumours: a systematic review and meta-analysis.
Tian SB; Tao KX; Hu J; Liu ZB; Ding XL; Chu YN; Cui JY; Shuai XM; Gao JB; Cai KL; Wang JL; Wang GB; Wang L; Wang Z
Sci Rep; 2017 Nov; 7(1):15500. PubMed ID: 29138453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]